D3 Drug Tech Lab Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 25-05-2024
- Paid Up Capital ₹ 0.11 M
as on 25-05-2024
- Company Age 3 Year, 2 Months
About D3 Drug Tech Lab
The Company is engaged in the Chemicals Industry.
The Company's status is Active It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.11 M, as per Ministry of Corporate Affairs (MCA) records.
Venkataraman Murali, Navabshan Irfan, Naleembukari Mohamedsaleem, and One other member serve as directors at the Company.
- CIN/LLPIN
U24239TN2021PTC146678
- Company No.
146678
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Sep 2021
- Date of AGM
-
- Date of Balance Sheet
-
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Dharmapuri, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at D3 Drug Tech Lab?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rizwan Navabjohn  | Director | 30-Sep-2021 | Current |
| Navabshan Irfan | Director | 30-Sep-2021 | Current |
| Venkataraman Murali | Director | 11-Jan-2023 | Current |
| Naleembukari Mohamedsaleem | Director | 30-Sep-2021 | Current |
Financial Performance and Corporate Structure Insights of D3 Drug Tech Lab.
Enhance accessibility to D3 Drug Tech Lab's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of D3 Drug Tech Lab?
Unlock access to D3 Drug Tech Lab's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Mi Traders And Services Private LimitedActive 5 years 10 monthsNaleembukari Mohamedsaleem and Rizwan Navabjohn are mutual person
Coda Technology Solutions Private LimitedActive 12 years 11 monthsNaleembukari Mohamedsaleem and Rizwan Navabjohn are mutual person
Net Carbon Vision Private LimitedActive 1 year 6 monthsVenkataraman Murali and Rizwan Navabjohn are mutual person
- Right Savour Ventures Private LimitedActive 2 years 21 days
Naleembukari Mohamedsaleem and Rizwan Navabjohn are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at D3 Drug Tech Lab?
D3 Drug Tech Lab has a workforce of 0 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of D3 Drug Tech Lab, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped D3 Drug Tech Lab's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
